Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Bill Cadwallader

PATH is an international nonprofit global health organization that was founded in 1977 and is headquartered in Seattle with 12+ employees in more than 3 offices around the world. PATH is one of the largest nonprofit organizations in global health today. PATH works on a wide array of emerging and persistent global health issues in the areas of health technologies maternal health child health reproductive health vaccines and immunization and emerging and epidemic diseases such as HIV malaria and tuberculosis. PATH is best known for developing and adapting technologies such as improved vaccination devices and new tools to prevent cervical cancer to address the health needs of developing countries. It targets health problems evaluates possible solutions and assesses whether they would be useful in finding health solutions.
Website:
www.path.org
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
PATH
Senior Commercialization Officer Diagnostics 

Andrea Cale

Website:
www.goodwinprocter.com
Goodwin Procter
Director Business Development - Technology & Life Sciences 

Cheryl Campbell United States

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Year Founded
2014
Main Sector
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Alliance & Collaborations
Massachusetts Institute of Technology and Massachusetts General Hospital
Current Financing Needs
$10M
IP Status
Application Filed
Recent Milestones
Finalist in MIT 100K Pitch 2014
Management Team Highlights
Harvard and MIT Collaborators
Cheryl Campbell
Biosight, LLC and MIT
LinkedIn logo MIT MBA Student and Intellectual Property Attorney 
BIO

A cancer scientist, corporate/IP lawyer and MBA candidate at the MIT Sloan School of Management who is dedicated to commercializing innovative biopharmaceutical products and medical devices that benefit patients. I have acquired diverse experience in the health care and life sciences industries spanning discovery, commercialization and regulatory development. My goal is to create and execute business and legal strategies that successfully drive products to market and create overall value for patient care. Capabilities include research design, assay development, clinical trial management, market/financial analysis, data modeling, operational design and management, system dynamics, drafting regulations, stakeholder engagement, intellectual property, licensing and contract drafting/negotiations.

Michael Cane United States

Westwood & Wilshire is a premier provider of executive search services to the Pharmaceutical, Biotechnology, Medical Devices and Diagnostics sectors.  Services include:

-Direct Hire Executive Search
-Interim Executive Search and Consultant Placement
-Board of Director and Advisory Group Development

Our clients range from Venture Capital-backed portfolio start ups to Fortune 500 Big Pharma. Our success encompasses executive level placements across Clinical, Medical, Regulatory, R&D, Quality and Commercial.

Website:
www.westwoodwilshire.com
Year Founded
2003
Service Provider Type
Sector Interest
Westwood & Wilshire LLC
Executive Recruiter 

Tom Capetan

The Foundation Fighting Blindness is a foundation founded in 1971 and headquartered in Colombia Maryland. The foundation typically makes allocations to companies in the range of $1-$8 million and is capable of providing $1-$15 over the investments lifetime. The firm does not look to take an equity position in companies but they do look for an ROI to return capital to the fund upon commercialization of the technology or change in ownership. The firm primarily funds companies located in the United States but will consider opportunities located globally as well. The firm provides equity capital and does look for a return though percentages taken are generally less than more financially motivated investors and all profits are reinvested back into the fund. Ideally the firm would like to allocate to 3-4 companies over the next 6-9 months.
Website:
www.fightblindness.org
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Foundation Fighting Blindness
Business Development 

Barbara Carlilse

Charles River discovery offers a truly integrated approach to small molecule drug discovery, uniting all of the key disciplines required to achieve a program's goals in a single project team. With the acquisition of BioFocus, Argenta and Chantest, the CRL Discovery organization can integrate medicinal chemistry, physical sciences, CADD, in vitro biology, HTS, structural biology, ADMET/PK and disease models as required.

Website:
www.criver.com
Service Provider Type
Sector Interest
Biotech Subsector
Unique Capabilities

Fully integrated services including:

Target Discovery

Complex in vitro Biology

HTS

Structural Biology

Medicinal Chemistry and CADD

Integrated Drug Discovery

Pharmaceutical Sciences

ADME/PK

In vivo services

BioFocus, A Charles River Company
Director Business Development 

Mark Carnegie

M.H. Carnegie & Co. founded in 21 is a venture capital and private equity firm based in Sydney Australia. The currently has about $2 million in committed capital across several funds. The firm invests in several sectors including the Life Sciences. The firm can make early to late stage investments typically allocating USD 2-5 million per company. The firm is currently interested in companies abroad that plan to set up operations in Australia as the firm is mandated to invest in Australian-based companies. The firm plans to make 2-3 new investments in the next 12 months and is actively seeking new opportunities.
Website:
www.mhcarnegie.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
M.H. Carnegie & Co.
Principle 

Dr Guy Carter United States

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076

Website:
www.biosortia.com
Year Founded
2008
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
Mobile, scalable, technology that maintains the integrity of the cell. Biosortia has proprietary methods & technologies that allow us to harvest unique single cellular micro-organism consortia never before studied and in unprecedented quantities targeting 500-1,000kg dry weight solids (DWS). Our technologies and capabilities open up this rich environment of bioactive and chemically diverse compounds for research in the pharmaceutical space for the first time ever. Biosortia’s relationship with NOAA and our Cooperative Research and Development Agreement (CRADA) with them provides Biosortia with identification and access to distinctly qualified harvest locations.
Alliance & Collaborations
(Eli Lilly, AstraZeneca, Eisai and Cubist Pharmaceuticals) with more in the pipeline.
Supporting Metrics or Evidence
Promising Early Results with big pharma (Eli Lilly, AstraZeneca, Eisai and Cubist Pharmaceuticals) with more in the pipeline. • Eli Lilly’s OIDD To date, nearly 100% of Compounds of Interest submitted into Eli Lilly’s Open Innovation Drug Discovery (OIDD) program have been accepted for evaluation…compared to an average 50-60% rejection rate on all submissions. This unprecedented achievement has recently earned Biosortia the inaugural “Collaborator of the Year” award from Lilly. In addition, due to the success in the OIDD Program, Lilly asked to join our Pharma Direct Model and test our fraction library. Initial results across simple 2 assays have produced 10 leads that they desire to follow-up in December 2014. • Big Pharma Interest As of September 30, 2014 we have 4 Big Pharma companies in our Pharma Direct Model (Eli Lilly, AstraZeneca, Cubist and Eisai) with 3 others in the pipeline in various stages of discussions.
Current Financing Needs
Capital- Biosortia has raised 2 rounds of series A Preferred Shares; November 2012 of $1.1M ($29M pre-money valuation) and September 2013 of $3.9M ($35M pre money valuation). In addition, it secured $1 million loan (2% interest) from the State of Ohio, therefore meeting our original desired capital raise of $4-5 million. The current raise is for $3-$6 million dollar to provide the runway to our first licensing agreement in Q4 2015 and drive the scaling of science capability to support the volume from our fraction libraries to be launched in Q1 of 2015.
Current Timeline
Hit rates well in excess of expectations Through our Pharma Direct Partners and 8 academic collaborators, we have over 50% of our fractions active against various therapy areas. This demonstrates both the richness of our compounds and the diversity across multiple therapy areas. With one of our Big Pharma partners alone, we have 48 active fractions/wells, with 20 showing inhibition of cancer growth from 90-99.8%. • Clear pathway to first license event in 2015 We can share with you a clear pathway to a license event in 2015. AZ, Lilly and Eisai are all on schedule to complete their R&D efforts by Q3 of 2015 that will put them in position to determine which compounds of interest they would like to license.
Recent Milestones
To date, nearly 100% of Compounds of Interest submitted into Eli Lilly’s Open Innovation Drug Discovery (OIDD) program have been accepted for evaluation…compared to an average 50-60% rejection rate on all submissions. This unprecedented achievement has recently earned Biosortia the inaugural “Collaborator of the Year” award from Lilly.
Management Team Highlights
Experienced Leadership Team & Advisors Biosortia’s leadership team has over 135 years of healthcare and life science experience with expertise in both pharmaceutical research and the micro-organism aquatic environments with the capability to provide new chemistry in a research ready format and co-develop with Pharma to pre-clinical. -Kurt D. Dieck, President and CEO - Mr. Dieck has spent 30 years in healthcare, including 18 years at Arthur Andersen where he was a global equity partner. In 2002, Kurt joined Cardinal Health, a Fortune 20 public company as a senior executive; where over his tenure he had responsibilities for Strategy, Business Development and ultimately SVP of Business Execution for the $100B pharmaceutical distribution segment. There he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Kurt also sits on two other healthcare related boards that are owned by Private Equity firms. -Guy T. Carter, Ph.D., Chief Scientific Officer – Dr. Carter has over 30 years of experience working in Pharmaceutical R&D, primarily in the discovery and development of microbial products. In the course of his career in the pharmaceutical industry he worked as a natural products discovery scientist and advanced through levels of scientific management to the overall leadership of the Natural Products Discovery function at Wyeth Research (later acquired by Pfizer), as well as directing other elements of the Chemical Technologies Department. Guy received a doctorate in Biochemistry from the University of Wisconsin-Madison, and then pursued marine natural products research on an NIH-sponsored post-doctoral fellowship with Kenneth Rinehart at the University of Illinois. -Haiyin He, Ph.D., VP of Research – Dr. He has more than 20 years of experience in pharmaceutical R&D, specializing in discovery of drug leads from natural products and their semi-synthetic analogs in oncology, infectious disease, and other therapeutic areas. Haiyin worked as a principle scientist III and group leader at Wyeth Research and after the merger between Pfizer and Wyeth, he continued on to work at Pfizer World Wide Medicinal Chemistry as an associate research fellow in the area of antibody-drug conjugates for cancer chemotherapy. Haiyin received a doctorate in marine natural products at Scripps Institution of Oceanography with John Faulkner, and then acquired a postdoctoral experience at Chemistry Department, Cornell University with Jon Clardy.
Dr Guy Carter
Biosortia Pharmaceuticals
LinkedIn logo CSO 

Gerard Casale

TYLT Lab was founded in 213 and has offices in Santa Monica CA and in Hong Kong. TYLT Lab invests across a variety of sectors including biotech and medical technology and will be raising a second fund in 215. TYLT Lab typically invests $5-$1 million and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year and is interested in opportunities globally, companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.
Website:
www.tyltlab.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
TYLT Lab
Managing Director 

David Cassak

Website:
www.medtechinno.com
Innovation in Medtech
Managing Director